Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease
Authors:
- 16 July 2025
- journal article
- Published by Elsevier in The Lancet Neurology
- Vol. 24 (8) , 634
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialThe Lancet Neurology, 2025
- Considering challenges for the new Alzheimer's drugs: Clinical, population, and health system perspectivesAlzheimer's & Dementia, 2024
- Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive AgingNeurology, 2023
- The prevalence, correlation, and co-occurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementiaThe Lancet Healthy Longevity, 2023